Advances in Antibody Mediated Rejection

Kidney transplantation is considered the treatment of choice for patients with end-stage renal disease, and is associated with improved survival, better quality of life and reduced costs when compared with dialysis.[1, 2] However, the renal transplantation waiting list is forever growing, out of proportion to the number of donors.[2, 3] Therefore it is all the more crucial to develop strategies to extend the life and functionality of every allograft.